Cutaneous leishmaniasis

The Lancet Infectious Diseases

Volumn 8, Issue 8, 2008, Pages 458-

  Khatami, Alireza ^a   Firooz, Alireza ^a   Gorouhi, Farzam ^a   Khamesiour, Ali ^a   Dowlati, Yahya ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; RIFAMPICIN;

CARBON DIOXIDE LASER; DRUG EFFICACY; HUMAN; LETTER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME;

EID: 47349106621     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70159-2     Document Type: Letter

References (13)

1. Reithinger R., Dujardin J.-C., Louzir H., Pirmez C., Alexander B., and Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 7 (2007) 581-596
2. Baily M., and Lockwood D. Cutaneous leishmaniasis. Clin Dermatol 25 (2007) 203-211
3. Asilian A., and Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 31 (2006) 634-637
4. 2 laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol 43 (2004) 736-738
5. Esfandiarpour I., and Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 41 (2002) 521-524
6. Vardy D., Barenholz Y., Naftoliev N., Klaus S., Gilead L., and Frankenburg S. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 95 (2001) 184-186
7. Kochar D., Aseri S., Sharma B., Bumb R., Mehta R., and Purohit S. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 93 (2000) 733-737
8. Firooz A., Khamesipour A., Ghoorchi M., et al. Imiquimod in combination with meglumine antimoniate for acute cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 142 (2006) 1575-1579
9. Momeni A., Reiszadae M., and Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 41 (2002) 441-443
10. Asilian A., Sadeghinia A., Faghihi G., and Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 43 (2004) 281-283
11. Khatami A., Firooz A., Gorouhi F., and Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57 (2007) 335.e1-335.e29
12. Mapar M., Kavoosi H., and Dabagh M. Assessment of the effect of topical opium in treatment of cutaneous leishmaniasis. Iranian J Dermatol 4 (2001) 23-28 (in Persian).
13. Gholami A., Khamesipour A., Momeni A., et al. Treatment of cutaneous leishmaniasis with 5% garlic cream: a randomized double blind study. Iranian J Dermatol 3 (2000) 2-6 (in Persian).